Skip to content
Peptigraph home

ATTAIN-2: Orforglipron Phase 3 trial (NCT05872620)

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)

Registry record checked

At a glance

Phase
Phase 3
Status
Completed
Enrolment
1,613
actual
Start
5 Jun 2023 (actual)
Primary completion
8 Aug 2025 (actual)
Sponsor
Eli Lilly and Company
Design

Arms and doses

NCT05872620 study arms
ArmTypeInterventionsDescription
PlaceboPlacebo comparatorDrug: PlaceboParticipants received matching placebo capsule orally once daily (QD). Treatment was initiated with placebo corresponding to 1 milligram (mg) equivalent to Orforglipron, with dose escalation every 4 weeks to maintain blinding, and was continued through Week 72, unless dose modification was required.
6 mg Orforglipron QDExperimentalDrug: OrforglipronParticipants received oral orforglipron capsule once daily. Treatment was initiated at 1 mg once daily, with dose escalation every 4 weeks to a target dose of 6 mg, which was maintained through Week 72, unless dose modification was required.
12 mg Orforglipron QDExperimentalDrug: OrforglipronParticipants received oral orforglipron capsule once daily. Treatment was initiated at 1 mg once daily, with dose escalation every 4 weeks to a target dose of 12 mg, which was maintained through Week 72, unless dose modification was required.
36 mg Orforglipron QDExperimentalDrug: OrforglipronParticipants received oral orforglipron capsule once daily. Treatment was initiated at 1 mg once daily, with dose escalation every 4 weeks to a target dose of 36 mg, which was maintained through Week 72, unless dose modification was required.
Endpoints

Primary endpoint

NCT05872620 primary outcomes
MeasureTime frame
Percent Change From Baseline in Body WeightBaseline, Week 72
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05872620 secondary outcomes
MeasureTime frame
Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From BaselineBaseline to Week 72
Percentage of Participants Who Achieved ≥10% Body Weight Reduction From BaselineBaseline to Week 72
Percentage of Participants Who Achieved ≥15% Body Weight Reduction From BaselineBaseline to Week 72
Change From Baseline in Waist CircumferenceBaseline, Week 72
Change From Baseline in Hemoglobin A1c (HbA1c) %Baseline, Week 72
Change From Baseline in Fasting Serum Glucose (FSG)Baseline, Week 72
Percentage of Participants Who Achieved Hemoglobin A1c (HbA1c) Target Value (<6.5%)Baseline to Week 72
Percentage of Participants Who Achieved Hemoglobin A1c (HbA1c) Target Value (<7.0%)Baseline to Week 72
Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)Baseline, Week 72
Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)Baseline, Week 72
Percent Change From Baseline in Fasting InsulinBaseline, Week 72
Percent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)Baseline, Week 72
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

Results are posted on the registry. Open the ClinicalTrials.gov record for NCT05872620.

ATTAIN-2 in adults with obesity and type 2 diabetes

Adults with a BMI of 27 or higher and HbA1c of 7-10% were randomised 1:1:1:2 to orforglipron 6, 12 or 36 mg or placebo once daily.[2]

Weight changed by -5.1%, -7.0% and -9.6% at 6, 12 and 36 mg against -2.5% on placebo (all p<0.0001).[2]

Discontinuation due to adverse events was 6.1-9.9% on orforglipron against 4.1% on placebo.[2]

Ten deaths were reported during the study, six on orforglipron and four on placebo, and investigators judged most unrelated to treatment.[2]

Sources

  1. 1A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026PMID 41275875Accessed 2 Oct 2026

Found an error? Report a correction.